Trials / Completed
CompletedNCT01052948
The Association Between Dopamine Agonists and Cardiac Valvulopathy, Fibrosis and Other Cardiopulmonary Events
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 86,939 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
To assess the association between cabergoline and other dopamine agonists (DAs), and symptomatic, diagnosed serious cardiopulmonary disorders, including: 1. Cardiac valve regurgitation 2. Diffuse Pleural/pulmonary thickening and pericardial and retroperitoneal fibrosis 3. Heart failure 4. Total, cardiac and respiratory mortality
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Retrospective study- | |
| OTHER | Retrospective study- | |
| OTHER | Retrospective study- | |
| OTHER | Retrospective study- |
Timeline
- Start date
- 2007-01-01
- Primary completion
- 2009-12-01
- Completion
- 2009-12-01
- First posted
- 2010-01-21
- Last updated
- 2011-03-23
- Results posted
- 2011-03-11
Source: ClinicalTrials.gov record NCT01052948. Inclusion in this directory is not an endorsement.